Orgenesis Inc. (NASDAQ:ORGS – Get Free Report) traded up 68.6% on Monday . The company traded as high as $0.59 and last traded at $0.59. Approximately 102 shares traded hands during trading, a decline of 89% from the average session volume of 971 shares. The stock had previously closed at $0.35.
Orgenesis Stock Performance
The stock’s 50-day moving average is $0.28 and its 200 day moving average is $0.36. The firm has a market cap of $3.05 million, a P/E ratio of -0.05 and a beta of 3.16.
Orgenesis Company Profile
Orgenesis, Inc is a cell and gene therapy company that develops and commercializes point-of-care manufacturing platforms for autologous and allogeneic therapies. The company offers an end-to-end solution that spans from R&D through clinical and commercial production, targeting applications in oncology, neurology, and various rare diseases. Orgenesis’ technology platforms are designed to streamline the complex processes involved in cell isolation, genetic modification, expansion and cryopreservation.
The company’s flagship offering is its automated Prodigy® platform, which integrates cell processing workflows into a closed, single-use system.
See Also
- Five stocks we like better than Orgenesis
- Movado’s Turnaround Gains Momentum
- Qualcomm’s Discount Could Vanish If Its AI Bet Pays Off
- Micron’s AI Memory Boom Could Send Shares 100% Higher
- Apple Stock Surges After Its Biggest Product Launch in Years—Can It Last?
Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.
